Walker J A, Sherman R A, Eisinger R P
Am J Kidney Dis. 1985 Oct;6(4):254-6. doi: 10.1016/s0272-6386(85)80183-9.
Desferrioxamine (DFO) was administered intravenously to a 63-year-old chronic hemodialysis patient with osteomalacia believed secondary to aluminum intoxication. Thrombocytopenia was noted after five doses of DFO. Platelet counts normalized after DFO was withheld. Thrombocytopenia recurred upon two rechallenges with this drug. It is suggested that platelet counts be monitored in hemodialysis patients receiving intravenous DFO.
去铁胺（DFO）静脉注射给了一名63岁的患有骨软化症的慢性血液透析患者，该骨软化症被认为继发于铝中毒。在给予五剂DFO后发现血小板减少。停用DFO后血小板计数恢复正常。再次使用该药物两次后血小板减少复发。建议对接受静脉注射DFO的血液透析患者监测血小板计数。
